GeneDx (NASDAQ:WGS) Sets New 52-Week High – What’s Next?

GeneDx Holdings Corp. (NASDAQ:WGS) hit a new 52-week high on Monday . The stock traded as high as $135.39 and last traded at $134.75, with a volume of 10410 shares traded. The stock had previously closed at $132.54.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised GeneDx from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Piper Sandler set a $120.00 target price on GeneDx and gave the company an “overweight” rating in a research note on Monday, August 4th. Wells Fargo & Company upped their target price on GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Finally, Guggenheim reaffirmed a “buy” rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $101.63.

GeneDx Stock Performance

The firm has a fifty day moving average price of $104.18 and a 200 day moving average price of $90.89. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The stock has a market cap of $3.85 billion, a PE ratio of 2,684.20 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.10 by $0.40. The firm had revenue of $102.69 million during the quarter, compared to analyst estimates of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. Research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc sold 500,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the transaction, the director directly owned 3,007,164 shares of the company’s stock, valued at approximately $363,566,127.60. This trade represents a 14.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 5,278 shares of the business’s stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total value of $490,854.00. Following the transaction, the chief financial officer owned 3,392 shares in the company, valued at approximately $315,456. This represents a 60.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 561,641 shares of company stock valued at $67,551,904. 29.60% of the stock is owned by corporate insiders.

Institutional Trading of GeneDx

Large investors have recently modified their holdings of the stock. Lazard Asset Management LLC purchased a new stake in shares of GeneDx during the fourth quarter worth $35,000. GAMMA Investing LLC increased its position in shares of GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after acquiring an additional 264 shares during the period. Comerica Bank purchased a new stake in shares of GeneDx during the fourth quarter worth $50,000. US Bancorp DE increased its position in shares of GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.